Liver
Purpose-built to Identify Treatment-Eligible MASH Patients
The approval of therapies for patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) has changed what providers need from non-invasive testing.
Historically, non-invasive tests have been used to identify advanced fibrosis and cirrhosis while helping assess the risk of future liver-related complications.1 Today, providers face an additional challenge: identifying treatment-eligible patients earlier in the disease course, before progression to advanced liver disease.
As treatment pathways evolve, understanding future risk remains important but must be complemented by accurate fibrosis staging. Together, this helps identify treatment-eligible patients while informing long-term patient management.
MASH Precis™ is a blood-based test purpose-built to help identify treatment-eligible F2-F3 patients (≥18 years of age) and support fibrosis assessment in the therapeutic era of MASH.
Why Early Identification Matters
MASH Often Progresses Silently
MASH often progresses silently, and may remain unrecognized until fibrosis has advanced, underscoring the importance of earlier assessment in individuals with cardiometabolic risk factors. As fibrosis progresses, the risk of cirrhosis, hepatocellular carcinoma and other serious liver-related complications increases.2-3
An estimated 60-80 million Americans have metabolic dysfunction-associated steatotic liver disease (MASLD), including 15-20 million who may have MASH,4 underscoring the need for scalable approaches to patient identification and fibrosis assessment.
Built for Today’s Treatment Decisions
Many existing non-invasive tests (NITs) were developed to assess advanced fibrosis. MASH Precis was designed with a different purpose: helping identify treatment-eligible F2-F3 patients and addressing an emerging need in evolving MASH care pathways.
Developed and validated using 906 biopsy-confirmed adult MASH patients, the proprietary MASH Precis Fibrosis Score utilizes an algorithm optimized to distinguish F2-F3 fibrosis from F0-F1 fibrosis and F4 cirrhosis.5
Actionable Results in a Single Report
MASH Precis combines fibrosis staging, prognostic risk assessment and biomarker insights into a single report designed to support patient evaluation and clinical decision making.
The report provides:
- Proprietary MASH Precis Fibrosis Score
- Enhanced Liver Fibrosis (ELF®) Risk Score
- Individual biomarker results
Together, these results provide complementary insights into disease severity and future liver-related risk.
References
1. Stefanakis K et al. Metabolism. 2025;169:156296.
2. Angulo P et al. Gastroenterology. 2015;149(2):389-397.e10.
3. Taylor RS et al. Gastroenterology. 2020;158(6):1611-1625.e12.
4. Le P et al. JAMA Netw Open. 2025;8(1):e2454707.
5. Data on file.
MASH Precis was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendment (CLIA) laboratory guidelines, and is performed exclusively in our high complexity CLIA certified and College of American Pathologists (CAP) accredited clinical laboratory. As a laboratory developed test, it has not been cleared or approved by the US FDA. MASH Precis may be covered by one or more US pending or issued patents – see prometheuslabs.com for details. Prometheus and MASH Precis are trademarks or registered trademarks of Prometheus Laboratories Inc, San Diego, California. All other trademarks and service marks are the property of their respective owners. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.